Martel Eye Medical Group | Rancho Cordova, CA

Research site

(Unclaimed)

Location

11216 Trinity River Drive, Rancho Cordova, California, United States of America

Site insights

Top conditions

Top treatments

KPI-121

AGN-190584

Bimatoprost

APP13007

Betamethasone Sodium Phosphate

DE-117

AGN-195263

TC-002

Azithromycin

Midazolam

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 34 total trials

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD)...

Enrolling

Age-Related Macular Degeneration

Drug: Placebo

Drug: Iptacopan (LNP023)

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. (UplighTED)

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod P...

Enrolling

Thyroid Eye Disease

Combination Product: Efgartigimod PH20 SC

Other: Placebo PH20 SC

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hyper...

Invitation-only

Open-Angle Glaucoma

Ocular Hypertension

Drug: Bimatoprost SR

Other: Standard of Care

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure (TC-002-301)

Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive ef...

Active, not recruiting

Elevated Intraocular Pressure

Drug: TC-002 latanoprost ophthalmic solution, 0.005%

Drug: Latanoprost ophthalmic solution, 0.005%

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational t...

Active, not recruiting

Neurotrophic Keratitis

Biological: CSB-001 Ophthalmic Solution 0.1%

Biological: Vehicle Control